ESMO 2026 Preview: Key studies that could fundamentally change the oncology landscape.
In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry,
insights
Preview, Uncategorized
A Progressive Reduction in Uncertainty
Strategic Intelligence Our clients don’t need more information. They need to know what matters. In a world of information abundance,
Eli Lilly top 2026 Global Pharmaceutical Innovation & Invention Index
Eli Lilly First Ever Company to Top Both Rankings in the 2026 Pharmaceutical Innovation and Invention Index See the full results at https://www.ideapharma.com/pii/report/global/ LONDON, UK — May 19th 2026 — The 2026 Global Pharmaceutical Innovation
2026 Freshness Index
The Freshness Index shows the percentage of company sales generated by products launched in the last three and five years.
Building the In Vivo Future: What Lilly’s Kelonia Bet Really Signals
By Amith Chordia and John Barry. Eli Lilly’s recent acquisition of Kelonia raised eyebrows, not because of what’s proven, but
The Future of Rare Disease: Engineered tRNA and a New Therapeutic Paradigm with Michelle Werner
In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a
The Emerging Innovative Pharmaceutical Enterprises in China
Building on the China Pharmaceutical Innovation and Invention Index, which assesses the overall innovation strength of leading Chinese pharmaceutical companies, here
Revitalizing Pharma Collaborations: The Reblozyl Case Study
In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the
Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan
In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about
Joint Clinical Assessment (EU HTA) Explained
A Comprehensive Exploration of Competitive Intelligence, Knowledge-Sharing, and Strategic Optimization in the Evolving Landscape of EU Health Technology Assessments. The